[go: up one dir, main page]

PE20191408A1 - Proteinas de union a antigeno st2 - Google Patents

Proteinas de union a antigeno st2

Info

Publication number
PE20191408A1
PE20191408A1 PE2019001319A PE2019001319A PE20191408A1 PE 20191408 A1 PE20191408 A1 PE 20191408A1 PE 2019001319 A PE2019001319 A PE 2019001319A PE 2019001319 A PE2019001319 A PE 2019001319A PE 20191408 A1 PE20191408 A1 PE 20191408A1
Authority
PE
Peru
Prior art keywords
seq
sequence
set forth
antibodies
pharmaceutical composition
Prior art date
Application number
PE2019001319A
Other languages
English (en)
Inventor
Dirk E Smith
Michael R Comeau
Randal R Ketchem
Donghui Shi
Xiaoshan Min
Ian Foltz
Chadwick T King
Ai Ching Lim
Rutilio Clark
Zhulun Wang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PE20191408A1 publication Critical patent/PE20191408A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)

Abstract

Referido a una composicion farmaceutica que comprende un anticuerpo dirigido contra el receptor de union para interleuquina-33 (ST2) que comprende un dominio variable de cadena ligera que comprende una secuencia LCDR1 que se establece en SEQ ID No:107; una secuencia LCDR2 que se establece en SEQ ID NO:118; y una secuencia LCDR3 que se establece en SEQ ID NO:129; y un dominio variable de cadena pesada que comprende una secuencia HCDR1 que se establece en SEQ ID NO: 41; una secuencia HCDR2 que se establece en SEQ ID NO:52; y una secuencia HCDR3 que se establece en SEQ ID NO:63; y un excipiente farmaceuticamente aceptable; en donde dicha composicion farmaceutica esta formulada para inyeccion subcutanea. Dicho anticuerpo reduce la senalizacion de ST2 mediada por IL-33 humano. Tambien se refiere a acidos nucleicos que codifican dichos anticuerpos y fragmentos de anticuerpo, variantes y derivados; ademas, se refiere a metodos para elaborar y usar dichos anticuerpos, incluidos metodos para tratar y prevenir trastornos autoinmunitarios e inflamatorios.
PE2019001319A 2012-05-18 2013-05-17 Proteinas de union a antigeno st2 PE20191408A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261649147P 2012-05-18 2012-05-18
US201361792619P 2013-03-15 2013-03-15
PCT/US2013/041656 WO2013173761A2 (en) 2012-05-18 2013-05-17 St2 antigen binding proteins

Publications (1)

Publication Number Publication Date
PE20191408A1 true PE20191408A1 (es) 2019-10-04

Family

ID=49584476

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2014002021A PE20150023A1 (es) 2012-05-18 2013-05-17 Proteinas de union a antigeno st2
PE2019001319A PE20191408A1 (es) 2012-05-18 2013-05-17 Proteinas de union a antigeno st2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2014002021A PE20150023A1 (es) 2012-05-18 2013-05-17 Proteinas de union a antigeno st2

Country Status (36)

Country Link
US (6) US9382318B2 (es)
EP (2) EP3693395A1 (es)
JP (6) JP6205410B2 (es)
KR (7) KR20200115662A (es)
CN (3) CN104334582B (es)
AP (1) AP2014008053A0 (es)
AR (1) AR091069A1 (es)
AU (2) AU2013262593B2 (es)
BR (1) BR112014028785B1 (es)
CA (2) CA3182435A1 (es)
CL (1) CL2014003131A1 (es)
CO (1) CO7250445A2 (es)
CR (2) CR20190225A (es)
DK (1) DK2850103T3 (es)
EA (1) EA035160B9 (es)
ES (1) ES2818571T3 (es)
HR (1) HRP20201341T1 (es)
HU (1) HUE052442T2 (es)
IL (4) IL282226B2 (es)
JO (1) JO3623B1 (es)
LT (1) LT2850103T (es)
MX (2) MX382398B (es)
MY (1) MY170099A (es)
NZ (1) NZ700856A (es)
PE (2) PE20150023A1 (es)
PH (1) PH12014502527B1 (es)
PL (1) PL2850103T3 (es)
PT (1) PT2850103T (es)
RS (1) RS60819B1 (es)
SG (1) SG11201407564TA (es)
SI (1) SI2850103T1 (es)
TN (1) TN2014000434A1 (es)
TW (1) TWI600664B (es)
UY (1) UY34813A (es)
WO (1) WO2013173761A2 (es)
ZA (1) ZA201407937B (es)

Families Citing this family (46)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US9090694B2 (en) 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
JO3623B1 (ar) 2012-05-18 2020-08-27 Amgen Inc Ų§Ł„ŲØŲ±ŁˆŲŖŁŠŁ†Ų§ŲŖ Ų§Ł„Ł…Ų±ŲŖŲØŲ·Ų© ŲØŁ…ŁˆŁ„ŲÆ Ų§Ł„Ł…Ų³ŲŖŲ¶Ų§ŲÆ st2
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma Ų§Ł„Ų£Ų¬Ų³Ų§Ł… Ų§Ł„Ł…Ų¶Ų§ŲÆŲ© Ł„Ł…Ų¶Ų§ŲÆ Ų§Ł†ŲŖŲ±Ł„ŁˆŁƒŁŠŁ†-33 ŁˆŲ§Ų³ŲŖŲ¹Ł…Ų§Ł„Ų§ŲŖŁ‡Ų§
MX364591B (es) 2013-03-15 2019-05-02 Regeneron Pharma Antagonistas de il-33 y usos de estos.
AU2015204674B2 (en) 2014-01-10 2020-09-03 Anaptysbio, Inc. Antibodies directed against interleukin-33 (IL-33)
US10040859B2 (en) 2014-04-21 2018-08-07 The Children's Hospital Of Philadelphia Methods of treating hemophagocytic lymphohistiocytosis with an IL-33 receptor antibody
EP3143404B1 (en) 2014-05-16 2018-08-29 Amgen Inc. Assay for detecting th1 and th2 cell populations
CN104017055B (zh) * 2014-06-27 2016-09-14 é¹æę·‘čŒ¹ äø€ē§å…³äŗŽst2蛋ē™½ęŠ‘åˆ¶å‰‚å¤šč‚½åŠå…¶åŗ”ē”Ø
CN104059130B (zh) * 2014-06-27 2016-08-24 ēŽ‹ę–¹ę° 关äŗŽst2蛋ē™½ęŠ‘åˆ¶å‰‚å¤šč‚½åŠå…¶åŗ”ē”Ø
CA2960297A1 (en) 2014-11-10 2016-05-19 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
CN107109494B (zh) 2014-11-10 2023-10-27 č±Ŗ夫čæˆĀ·ē½—ę°ęœ‰é™å…¬åø Il-33介åƼ型ē–¾ē—…ēš„ę²»ē–—ę–¹ę³•å’ŒčÆŠę–­ę–¹ę³•
WO2016122865A1 (en) 2015-01-30 2016-08-04 Salk Institute For Biological Studies Compositions and methods for treating age-related diabetes and related disorders
NZ736026A (en) 2015-03-31 2023-02-24 Medimmune Ltd A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
WO2017083242A1 (en) 2015-11-13 2017-05-18 The Regents Of The University Of Michigan Inhibitors of suppression of tumorigencity 2 (st2) and methods using the same
US20180346571A1 (en) * 2015-11-17 2018-12-06 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
EA201891628A1 (ru) * 2016-01-14 2018-12-28 ŠŠ½Š°ŠæтŠøсŠ±Š°Š¹Š¾, Š˜Š½Šŗ. Š˜Š½Š³ŠøŠ±ŠøрŠ¾Š²Š°Š½ŠøŠµ Š°Š»Š»ŠµŃ€Š³ŠøчŠµŃŠŗŠ¾Š¹ рŠµŠ°ŠŗцŠøŠø с ŠøсŠæŠ¾Š»ŃŒŠ·Š¾Š²Š°Š½ŠøŠµŠ¼ ŠøŠ½Š³ŠøŠ±ŠøтŠ¾Ń€Š° il-33
MX2018013038A (es) 2016-04-27 2019-03-28 Pfizer Anticuerpos anti-il-33, composiciones, metodos y usos de los mismos.
CN107446040B (zh) * 2016-05-30 2021-01-12 ę·±åœ³åø‚安ē¾¤ē”Ÿē‰©å·„ēØ‹ęœ‰é™å…¬åø äŗŗst2ęŠ—åŽŸč”Øä½č‚½ć€ęŠ—åŽŸć€ęŠ—ä½“ć€čƕ剂ē›’及åŗ”ē”Ø
CN107765014B (zh) * 2016-08-23 2019-11-19 äøŠęµ·č“¹ēŽ›ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø äø€ē§ę£€ęµ‹äŗŗsST2蛋ē™½ēš„ę–¹ę³•ä»„及čƕ剂ē›’
TWI857389B (zh) 2016-12-01 2024-10-01 ē¾Žå•†å†ē”Ÿå…ƒé†«č—„公åø ę²»ē™‚ē™¼ē‚Žē—‡ē‹€ēš„ę–¹ę³•
WO2018112069A1 (en) 2016-12-13 2018-06-21 Delinia, Inc. Multivalent regulatory t cell modulators
PE20191548A1 (es) 2017-02-10 2019-10-24 Genentech Inc Anticuerpos contra triptasa, composiciones de estos y usos de estos
CN110573174A (zh) * 2017-02-17 2019-12-13 通ē”Ø医ē–—å…¬åø ē”ØäŗŽę²»ē–—č„‘ęŸä¼¤ēš„ę–¹ę³•å’Œē»„合ē‰©
AU2018252974B2 (en) 2017-04-13 2024-10-17 Regeneron Pharmaceuticals, Inc. Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1
PE20211304A1 (es) 2018-02-09 2021-07-20 Genentech Inc Metodos terapeuticos y diagnosticos para enfermedades inflamatorias mediadas por mastocitos
IL277890B2 (en) * 2018-04-11 2024-03-01 Regeneron Pharma Methods for quantifying il-33
WO2020028784A1 (en) * 2018-08-03 2020-02-06 The Trustees Of Indiana University Methods for targeting, inhibiting, and treating a tumor microenvironment
CN113286814A (zh) * 2018-10-31 2021-08-20 德里尼äŗšå…¬åø å¤šä»·č°ƒčŠ‚ę€§tē»†čƒžč°ƒčŠ‚子
US11739156B2 (en) * 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
WO2020244544A1 (zh) 2019-06-04 2020-12-10 ę±Ÿč‹ę’ē‘žåŒ»čÆč‚”ä»½ęœ‰é™å…¬åø čƒ½ē»“合čƒøč…ŗåŸŗč“Øę·‹å·“ē»†čƒžē”Ÿęˆē“ ēš„ęŠ—ä½“åŠå…¶åŗ”ē”Ø
CN110357963B (zh) * 2019-07-31 2020-09-18 北äŗ¬ę™ŗ仁ē¾Žåšē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø ꊗäŗŗst2ęŠ—ä½“åŠå…¶ē”Ø途
JP2023500492A (ja) 2019-11-04 2023-01-06 ćƒ”ćƒ‰ć‚¤ćƒŸćƒ„ćƒ¼ćƒ³ćƒ»ćƒŖ惟惆惃惉 ļ¼©ļ½Œļ¼ļ¼“ļ¼“ć‚¢ćƒ³ć‚æć‚“ćƒ‹ć‚¹ćƒˆć®ä½æē”Øę–¹ę³•
CA3158366A1 (en) 2019-11-04 2021-05-14 Medimmune Limited Anti il-33 therapeutic agent fpr treating renal disorders
CN110921675A (zh) * 2019-11-27 2020-03-27 ęˆéƒ½ē†å·„大学 äø€ē§å­”ēŠ¶CaB6ēŗ³ē±³ę£’ēš„åˆ¶å¤‡ę–¹ę³•
CN113214395A (zh) * 2020-01-21 2021-08-06 čæˆå؁(äøŠęµ·)ē”Ÿē‰©ē§‘ęŠ€č‚”ä»½ęœ‰é™å…¬åø ꊗst2ęŠ—ä½“åŠå…¶åŗ”ē”Ø
CN111308086B (zh) * 2020-02-21 2022-02-25 č‹å·žę—­å…‰ē§‘ę˜ŸęŠ—ä½“ē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø äø€ē§ę£€ęµ‹åÆęŗ¶ę€§st2含量ēš„é…¶č”å…ē–«ę£€ęµ‹čƕ剂ē›’及ē”Ø途
TW202144410A (zh) 2020-03-13 2021-12-01 ē¾Žå•†å»ŗ南德克公åø ꊗ介ē™½ē“ ļ¼ļ¼“ļ¼“ęŠ—é«”åŠå…¶ē”Ø途
US20230110203A1 (en) 2020-03-13 2023-04-13 Medimmune Limited Therapeutic methods for the treatment of subjects with risk alelles in il33
KR20220164555A (ko) 2020-04-06 2022-12-13 ė©”ė””ė®Ø ė¦¬ėÆøķ‹°ė“œ Il-33 ģ¶• ź²°ķ•© źøøķ•­ģ œė„¼ ģ‚¬ģš©ķ•œ źø‰ģ„± ķ˜øķ” ź³¤ėž€ ģ¦ķ›„źµ°ģ˜ ģ¹˜ė£Œ
US20230272086A1 (en) * 2020-05-12 2023-08-31 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. St2 antigen binding protein
DK4238095T3 (da) * 2020-11-02 2025-10-13 Regeneron Pharma FremgangsmƄder og systemer til bioterapeutisk udvikling
MX2023014658A (es) 2021-06-11 2024-01-12 Genentech Inc Metodo para tratar la enfermedad pulmonar obstructiva cronica con un antagonista de st2.
CN116284388A (zh) * 2021-07-21 2023-06-23 čæˆå؁(äøŠęµ·)ē”Ÿē‰©ē§‘ęŠ€č‚”ä»½ęœ‰é™å…¬åø ꊗč‚æē˜¤ęŠ‘制ē“ 2ēš„ęŠ—ä½“ä»„及包含其ēš„ę¶²ä½“ē»„合ē‰©
CN115920033A (zh) * 2021-07-21 2023-04-07 čæˆå؁(äøŠęµ·)ē”Ÿē‰©ē§‘ęŠ€č‚”ä»½ęœ‰é™å…¬åø ꊗč‚æē˜¤ęŠ‘制ē“ 2ęŠ—ä½“ēš„制čÆē”Ø途
EP4430072A1 (en) 2021-11-10 2024-09-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2024148263A1 (en) * 2023-01-06 2024-07-11 Victorian Infectious Diseases Reference Laboratory Methods and compositions for antibody treatment of hepatitis b infection

Family Cites Families (190)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 å‘³ć®ē“ ę Ŗ式会ē¤¾ 代ē”Øč”€ę¶²
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikƶrpern
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO1992015673A1 (en) 1991-03-11 1992-09-17 The University Of Georgia Research Foundation, Inc. Cloning and expression of renilla luciferase
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikƶrpern auf phagenoberflƤchen ausgehend von antikƶrpersegmentbibliotheken
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
JP3589665B2 (ja) 1992-10-23 2004-11-17 ć‚¤ćƒŸćƒ„ćƒćƒƒć‚Æć‚¹ćƒ»ć‚³ćƒ¼ćƒćƒ¬ćƒ¼ć‚·ćƒ§ćƒ³ åÆęŗ¶ę€§ć‚ŖćƒŖć‚“ćƒžćƒ¼č›‹ē™½č³Ŗ恮čŖæč£½ę³•
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
JPH0731479A (ja) * 1993-02-23 1995-02-03 Shinichi Tominaga ćƒžć‚¦ć‚¹ļ½“ļ½”ļ¼’ļ½Œć‚’ć‚³ćƒ¼ćƒ‰ć™ć‚‹ļ½„ļ½Žļ½ć€č©²ļ½„ļ½Žļ½ć®ē™ŗē¾ē”£ē‰©ć€č©²ļ½„ļ½Žļ½ć‚’ē™ŗē¾ć•ć›ć‚‹ć“ćØć«ć‚ˆć‚‹ē™ŗē¾ē”£ē‰©ć®č£½é€ ę–¹ę³•
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
JP3810791B2 (ja) 1993-09-10 2006-08-16 ć‚¶ćƒ»ćƒˆćƒ©ć‚¹ćƒ†ć‚£ćƒ¼ć‚ŗ惻ć‚Ŗćƒ–ćƒ»ć‚³ćƒ©ćƒ³ćƒ“ć‚¢ćƒ»ćƒ¦ćƒ‹ćƒćƒ¼ć‚·ćƒ†ć‚£ćƒ¼ćƒ»ć‚¤ćƒ³ćƒ»ć‚¶ćƒ»ć‚·ćƒ†ć‚£ćƒ¼ćƒ»ć‚Ŗćƒ–ćƒ»ćƒ‹ćƒ„ćƒ¼ćƒØćƒ¼ć‚Æ ē·‘č‰²č›å…‰ć‚æćƒ³ćƒ‘ć‚Æč³Ŗ恮ä½æē”Ø
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US7473423B2 (en) 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US5576191A (en) * 1994-06-17 1996-11-19 Immunex Corporation Cytokine that binds ST2
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US6455685B1 (en) 1995-03-03 2002-09-24 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US6037525A (en) 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikƶrper die EGFR binden
DE69732667T2 (de) 1996-12-12 2006-01-19 Prolume, Ltd., Beverly Hills Vorrichtung und verfahren zum nachweis und identifizieren von infektiƶsen wirkstoffen
DE19711932A1 (de) 1997-03-21 1998-09-24 Anne Katrin Dr Werenskiold In vitro-Verfahren zum Prognostizieren des Krankheitsverlaufs von Patienten mit Mammakarzinom und/oder zum Diagnostizieren eines Mammakarzinoms
US6245974B1 (en) 1997-08-06 2001-06-12 North Carolina State University Matrix attachment regions
US6326472B1 (en) 1997-10-15 2001-12-04 Schering Corporation Human receptor proteins; related reagents and methods
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
GB9727172D0 (en) 1997-12-24 1998-02-25 Univ Glasgow Reagents specific for st2l and uses therefor
EP1064360B1 (en) 1998-03-27 2008-03-05 Prolume, Ltd. Luciferases, gfp fluorescent proteins, their nucleic acids and the use thereof in diagnostics
US6177612B1 (en) 1998-07-31 2001-01-23 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada Matrix attachment regions
WO2000018938A1 (en) 1998-09-29 2000-04-06 Pioneer Hi-Bred International, Inc. Mar/sar elements flanking rsyn7-driven construct
AU5309600A (en) 1999-06-02 2000-12-18 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US20030152926A1 (en) 1999-08-11 2003-08-14 Eos Biotechnology, Inc. Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
CA2388063C (en) 1999-11-24 2010-06-08 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US6566130B1 (en) 2000-01-28 2003-05-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Androgen-regulated gene expressed in prostate tissue
AU2001218871A1 (en) 2000-03-21 2001-10-03 Takao Arai Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
KR100408844B1 (ko) 2000-07-29 2003-12-06 ķ•œźµ­ģ‚°ģ—…źø°ģˆ ķ‰ź°€ģ› ė™ė¬¼ģ„øķ¬ ė°œķ˜„ė²”ķ„°
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
CA2426540A1 (en) 2000-10-20 2002-07-25 Biocardia, Inc. Leukocyte expression profiling
US7259010B2 (en) 2000-12-15 2007-08-21 Pangen Biotech Inc. Expression vector for animal cell containing nuclear matrix attachment region of interferon beta
WO2002068579A2 (en) 2001-01-10 2002-09-06 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
ATE437233T1 (de) 2001-01-26 2009-08-15 Selexis Sa Matrix-anheftungsregionen und verfahren zu deren verwendung
AU2002306768A1 (en) 2001-03-20 2002-10-03 Ortho-Clinical Diagnostics, Inc. Expression profiles and methods of use
EP1409504A2 (en) 2001-03-29 2004-04-21 Incyte Genomics, Inc. Secretory molecules
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
AU2002324700A1 (en) 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
EP1446507A2 (en) 2001-10-31 2004-08-18 Pfizer Products Inc. Therapeutics and diagnostics for disorders of erythropoiesis
US7504222B2 (en) 2001-10-31 2009-03-17 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US7507787B2 (en) 2001-12-03 2009-03-24 The University Of British Columbia Effectors of innate immunity
KR20040077669A (ko) 2001-12-03 2004-09-06 ģœ ė‹ˆė²„ģ‹œķ‹° ģ˜¤ėøŒ ėøŒė¦¬ķ‹°ģ‹œ ģ½œė”¬ė¹„ģ•„ ģ„ ģ²œ ė©“ģ—­ģ˜ ģž‘ė™ģ²“
US20060046249A1 (en) 2002-01-18 2006-03-02 Fei Huang Identification of polynucleotides and polypetide for predicting activity of compounds that interact with protein tyrosine kinase and or protein tyrosine kinase pathways
JP2003235573A (ja) 2002-02-13 2003-08-26 Sumitomo Pharmaceut Co Ltd ē³–å°æē—…ꀧ腎ē—‡ćƒžćƒ¼ć‚«ćƒ¼ćŠć‚ˆć³ćć®åˆ©ē”Ø
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2003080640A1 (en) 2002-03-07 2003-10-02 Ludwig Institute For Cancer Research Lymphatic and blood endothelial cell genes
US20030224422A1 (en) 2002-04-08 2003-12-04 St. Jude Children's Research Hospital, Inc. Pre-and post therapy gene expression profiling to identify drug targets
EP1578918A2 (en) 2002-04-23 2005-09-28 Duke University Atherosclerotic phenotype determinative genes and methods for using the same
WO2003094856A2 (en) 2002-05-09 2003-11-20 The Brigham And Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker and therapeutic target
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domƦner og dobbeltspecifikke konstruktioner deraf
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 갗ē®”ę”Æ喘ęÆć¾ćŸćÆę…¢ę€§é–‰å”žę€§č‚ŗē–¾ę‚£ć®ę¤œęŸ»ę–¹ę³•
JP2006500364A (ja) 2002-08-16 2006-01-05 ć‚¤ćƒ ćƒŽćƒ¼ć‚øć‚§ćƒ³ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ćƒ¼ćƒ†ćƒƒćƒ‰ é«˜ć„ååæœę€§ćØęŗ¶č§£åŗ¦ć‚’ęœ‰ć™ć‚‹ęž¶ę©‹å‰¤ćŠć‚ˆć³å°åˆ†å­č–¬ē‰©ć®ęؙēš„化送達ē”Øć‚³ćƒ³ć‚øćƒ„ć‚²ćƒ¼ćƒˆć®čŖæč£½ć«ćŠć‘ć‚‹ćć‚Œć‚‰ć®ä½æē”Ø
EP1542724A4 (en) * 2002-08-19 2005-10-19 Abgenix Inc ANTIBODIES AGAINST THE MONOCYTE 1 CHIMIOATTRACTIVE PROTEIN (MCP-1) AND USES THEREOF
PL377091A1 (pl) * 2002-09-06 2006-01-23 Amgen, Inc. Ludzkie monoklonalne przeciwciało przeciw-IL-1R1, o właściwościach terapeutycznych
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
AU2003290537A1 (en) 2002-10-24 2004-05-13 Duke University Binary prediction tree modeling with many predictors and its uses in clinical and genomic applications
US20040106113A1 (en) 2002-10-24 2004-06-03 Mike West Prediction of estrogen receptor status of breast tumors using binary prediction tree modeling
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7217807B2 (en) 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
US20070015152A1 (en) 2002-12-12 2007-01-18 Novartis Ag Methods for diagnosing and treating schizophrenia
US20070042978A1 (en) 2002-12-19 2007-02-22 Jean-Philippe Girard Nf-hev compositions and methods of use
ES2388280T3 (es) 2002-12-20 2012-10-11 Abbott Biotherapeutics Corp. Anticuerpos que reaccionan frente a GPR64 y utilizaciĆ³n de los mismos
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
US20040219579A1 (en) 2003-02-19 2004-11-04 Natasha Aziz Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2004083818A2 (en) 2003-03-17 2004-09-30 Rinat Neuroscience Corp. Methods of identifying drug targets and modulators of neurons and compositions comprising the same
US7755007B2 (en) 2003-04-17 2010-07-13 K&H Manufacturing, Inc Heated pet mat
JP2006526405A (ja) 2003-06-04 2006-11-24 ć‚Øćƒ¼ć‚øć‚§ćƒ³ć‚·ćƒ¼ ćƒ•ć‚©ćƒ¼ 悵悤ć‚Øćƒ³ć‚¹ļ¼Œćƒ†ć‚Æ惎惭ć‚øćƒ¼ ć‚¢ćƒ³ćƒ‰ ćƒŖć‚µćƒ¼ćƒ ē¤ŗå·®ēš„čŖæēÆ€ć•ć‚ŒćŸč‚ē“°čƒžē™Œéŗä¼å­ćŠć‚ˆć³ćć®åˆ©ē”Ø
AU2004245998A1 (en) 2003-06-04 2004-12-16 The Government of the United States as represented by The Secretary of the Department of Health and Human Services, Centres for Disease Control and Prevention PNI microarray and uses
US20090227464A1 (en) 2003-07-01 2009-09-10 Smadar Avigad Prognosis determination in ewing sarcoma patients by means of genetic profiling
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
CN1938428A (zh) 2003-11-12 2007-03-28 先ēµå…¬åø 多åŸŗ因č”Øč¾¾ēš„č“Øē²’ē³»ē»Ÿ
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
JP2005204549A (ja) 2004-01-21 2005-08-04 Hubit Genomix Inc ļ¼£åž‹č‚ē‚Žć‚¦ć‚¤ćƒ«ć‚¹ę„ŸęŸ“者恮ēµŒéŽć«é–¢ć™ć‚‹éŗä¼å­ćŠć‚ˆć³ćć®åˆ©ē”Ø
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
WO2005084390A2 (en) 2004-03-02 2005-09-15 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
CA2561742A1 (en) 2004-04-01 2005-10-27 Sequenom, Inc. Methods for identifying risk of osteoarthritis and treatments thereof
WO2005108415A2 (en) 2004-04-30 2005-11-17 Biogen Idec Ma Inc. Membrane associated molecules
MXPA06014065A (es) 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
AU2005316844A1 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
WO2007019232A2 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
JP5167130B2 (ja) 2005-08-09 2013-03-21 ćƒŸćƒ¬ćƒ‹ć‚¢ćƒ  ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗļ¼Œ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ć‚­ćƒ©ćƒ«ć‚¢ćƒŸćƒŽé…øć‚’ęœ‰ć™ć‚‹ćƒ”ć‚¤ć‚æćƒ³ć‚·ćƒŽćƒ¼ćƒ«ć®ć‚¢ć‚·ćƒ«åŒ–ę–¹ę³•
CN101395920A (zh) 2006-03-01 2009-03-25 ę±¤å§†ę£®ē‰¹č®ø公åø ē”ŸęˆåŖ’体包ēš„č®¾å¤‡äøŽę–¹ę³•
WO2007127749A2 (en) 2006-04-24 2007-11-08 Critical Care Diagnostics, Inc. Predicting mortality and detecting severe disease
US8865645B2 (en) 2006-05-24 2014-10-21 Biogen Idec Ma Inc. Method of treating lung fibrosis using ST2 polypeptide
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
WO2008024919A2 (en) 2006-08-23 2008-02-28 University Of Medicine And Dentistry Of New Jersey Interferon antagonists, antibodies thereto, and associated methods of use
IE20080331A1 (en) 2007-04-26 2009-07-08 Trinity College Dublin Products for altering cytokine activity and methods therefor
US20100260770A1 (en) 2007-05-18 2010-10-14 Medimmune, Llc Il-33 in inflammatory disease
MY150531A (en) 2007-07-16 2014-01-30 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc MĆ©todo de preparaĆ§Ć£o de molĆ©culas heterodimĆ©ricas de fc de anticorpos utilizando efeitos de induĆ§Ć£o eletrostĆ”tica
DK2657253T3 (en) 2008-01-31 2017-10-09 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
RU2607569C2 (ru) 2008-03-31 2017-01-10 Š”Š¶ŠµŠ½ŠµŠ½Ń‚ŠµŠŗ, Š˜Š½Šŗ. ŠšŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø Šø сŠæŠ¾ŃŠ¾Š±Ń‹ Š“Š»Ń Š»ŠµŃ‡ŠµŠ½Šøя Šø Š“ŠøŠ°Š³Š½Š¾ŃŃ‚ŠøŠŗŠø Š°ŃŃ‚Š¼Ń‹
CN102076717B (zh) 2008-04-30 2016-02-03 伊ē¼ŖčÆŗ金公åø äŗ¤č”剂和它们ēš„ē”Ø途
US8298533B2 (en) * 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
US7879978B2 (en) * 2009-03-31 2011-02-01 Centocor Ortho Biotech, Inc. Macaca fascicularis ST2L
WO2011031600A1 (en) 2009-09-10 2011-03-17 Schering Corporation Use of il-33 antagonists to treat fibrotic disease
EP3434694B1 (en) 2010-04-09 2020-12-30 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
KR101615474B1 (ko) 2010-12-16 2016-04-25 ģ œė„Øķ…Œķ¬, ģøķ¬. Th2 ģ–µģ œģ— ź“€ķ•œ ģ§„ė‹Ø ė° ģ¹˜ė£Œ
BR112013021473A2 (pt) * 2011-02-23 2020-08-04 F. Hoffmann-La Roche Ag anticorpos contra il33r humano e seus usos
US9090694B2 (en) * 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
JO3623B1 (ar) * 2012-05-18 2020-08-27 Amgen Inc Ų§Ł„ŲØŲ±ŁˆŲŖŁŠŁ†Ų§ŲŖ Ų§Ł„Ł…Ų±ŲŖŲØŲ·Ų© ŲØŁ…ŁˆŁ„ŲÆ Ų§Ł„Ł…Ų³ŲŖŲ¶Ų§ŲÆ st2
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma Ų§Ł„Ų£Ų¬Ų³Ų§Ł… Ų§Ł„Ł…Ų¶Ų§ŲÆŲ© Ł„Ł…Ų¶Ų§ŲÆ Ų§Ł†ŲŖŲ±Ł„ŁˆŁƒŁŠŁ†-33 ŁˆŲ§Ų³ŲŖŲ¹Ł…Ų§Ł„Ų§ŲŖŁ‡Ų§
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
HRP20201341T1 (hr) 2020-11-27
PT2850103T (pt) 2020-10-01
AU2013262593B2 (en) 2018-01-25
DK2850103T3 (da) 2020-09-07
JP6205410B2 (ja) 2017-09-27
AU2018202097A1 (en) 2018-05-31
EP2850103B1 (en) 2020-07-22
US20140004107A1 (en) 2014-01-02
CR20190225A (es) 2019-06-07
BR112014028785B1 (pt) 2023-02-28
CA2873549A1 (en) 2013-11-21
KR102161460B1 (ko) 2020-10-07
CN116333114A (zh) 2023-06-27
US20190359720A1 (en) 2019-11-28
MX382398B (es) 2025-03-13
TWI600664B (zh) 2017-10-01
US20170002079A1 (en) 2017-01-05
KR20220107316A (ko) 2022-08-02
MX2014013894A (es) 2015-01-16
CN109206517B (zh) 2022-12-02
CL2014003131A1 (es) 2015-02-20
CA2873549C (en) 2023-02-28
PL2850103T3 (pl) 2020-12-14
AP2014008053A0 (en) 2014-11-30
IL282226B2 (en) 2024-05-01
ES2818571T3 (es) 2021-04-13
NZ700856A (en) 2017-03-31
JP2019004885A (ja) 2019-01-17
AU2013262593A1 (en) 2014-10-30
AR091069A1 (es) 2014-12-30
EA201492149A8 (ru) 2015-10-30
EP2850103A2 (en) 2015-03-25
CA3182435A1 (en) 2013-11-21
PE20150023A1 (es) 2015-01-22
ZA201407937B (en) 2017-09-27
KR20230043229A (ko) 2023-03-30
LT2850103T (lt) 2020-12-10
HUE052442T2 (hu) 2021-04-28
US9982054B2 (en) 2018-05-29
TW201350506A (zh) 2013-12-16
PH12014502527A1 (en) 2015-01-12
EA035160B1 (ru) 2020-05-08
IL267599A (en) 2019-08-29
KR20200115662A (ko) 2020-10-07
JP2022106790A (ja) 2022-07-20
PH12014502527B1 (en) 2020-11-11
US20240368292A1 (en) 2024-11-07
CN104334582B (zh) 2018-10-26
TN2014000434A1 (en) 2016-03-30
BR112014028785A2 (pt) 2017-07-18
EA201492149A1 (ru) 2015-03-31
US9382318B2 (en) 2016-07-05
WO2013173761A2 (en) 2013-11-21
CO7250445A2 (es) 2015-04-30
EP3693395A1 (en) 2020-08-12
IL282226A (en) 2021-05-31
CN104334582A (zh) 2015-02-04
MX356557B (es) 2018-06-04
IL235308A0 (en) 2014-12-31
KR20240130810A (ko) 2024-08-29
US20170267769A1 (en) 2017-09-21
JP2015523967A (ja) 2015-08-20
EP2850103A4 (en) 2016-08-31
RS60819B1 (sr) 2020-10-30
SG11201407564TA (en) 2014-12-30
KR20150013167A (ko) 2015-02-04
WO2013173761A3 (en) 2014-02-20
IL282226B1 (en) 2024-01-01
IL267599B (en) 2021-04-29
JP2024174933A (ja) 2024-12-17
KR20250043598A (ko) 2025-03-28
HK1208479A1 (en) 2016-03-04
KR20230170805A (ko) 2023-12-19
EA035160B9 (ru) 2020-10-01
SI2850103T1 (sl) 2021-01-29
IL308770A (en) 2024-01-01
MY170099A (en) 2019-07-05
CR20140585A (es) 2015-03-06
US20220119537A1 (en) 2022-04-21
US11965029B2 (en) 2024-04-23
JP2020171305A (ja) 2020-10-22
US11059895B2 (en) 2021-07-13
CN109206517A (zh) 2019-01-15
JO3623B1 (ar) 2020-08-27
US10227414B2 (en) 2019-03-12
UY34813A (es) 2013-11-29
JP2016180001A (ja) 2016-10-13
JP6382260B2 (ja) 2018-08-29

Similar Documents

Publication Publication Date Title
PE20191408A1 (es) Proteinas de union a antigeno st2
PE20141151A1 (es) Proteinas de union al antigeno cd27l
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
NZ600512A (en) Neutralizing prolactin receptor antibodies and their therapeutic use
PE20130226A1 (es) Anticuerpos hacia gdf8 humano
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
PE20210045A1 (es) Anticuerpos agonistas contra pd-1 y usos de estos
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
NZ603607A (en) Cgrp antibodies
CO6230999A2 (es) Anticuerpo anti-esclerostina
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
PE20210115A1 (es) Anticuerpos anti-tau y uso de los mismos
NZ628943A (en) Human antibodies to clostridium difficile toxins
PE20191045A1 (es) Anticuerpos anti-il-33 y usos de los mismos
PE20081503A1 (es) Miembros de union para il-6
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
NZ729158A (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
AR110203A1 (es) Anticuerpos anti-tim-3 para combinaciĆ³n con anticuerpos anti-pd-1
PE20150159A1 (es) Composiciones y metodos para anticuerpos que actuan sobre el factor p
NZ608660A (en) Anti-cd48 antibodies and uses thereof
PE20142170A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
PE20170916A1 (es) Composiciones y metodos para anticuerpos dirigidos a bmp6